Pay in 4 interest-free payments of $5.07 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
| Category | Zepbound | Mounjaro | |-----------------------------------|------------------------------------------------|------------------------------------------------| | FDA Approval Indication | Obesity and overweight management (with comorbidities) | Type 2 diabetes management | | Year of FDA Approval | 2023 | 2022 | | Active Ingredient | Tirzepatide | Tirzepatide | | Dose Range | 2.5 mg to 15 mg once weekly | 2.5 mg to 15 mg once weekly | | Primary Clinical Purpose | Weight loss | Blood sugar control | | GLP-1/GIP Activity | Dual agonist (GLP-1 + GIP) | Dual agonist (GLP-1 + GIP) | | Average Weight Loss (in trials) | Up to 22.5% of body weight in SURMOUNT-1 study | Up to 15% of body weight in SURPASS studies | | Insulin Sensitivity Impact | Improves insulin sensitivity in patients with obesity | Improves insulin sensitivity in type 2 diabetes patients | | Delivery Method | Single-use auto-injector pen, subcutaneous injection | Single-use auto-injector pen, subcutaneous injection | | Dosing Frequency | Once weekly | Once weekly | | Manufacturer | Eli Lilly | Eli Lilly | | Common Side Effects | Nausea, vomiting, diarrhea, constipation, decreased appetite | Nausea, vomiting, diarrhea, constipation, decreased appetite | | Insurance Coverage | Variable
Once-weekly injection Convenient dosing : Mounjaro is administered once a week, making it more convenient compared to other weight loss injections that may require more frequent administration (e.g., daily or multiple times a week)
It should be under your doctors monitoring
Many people experience less nausea, bloating, or fatiguemaking long-term use more comfortable and sustainable
